CERT · Certara, Inc. · Executive Compensation
$11.26
-0.14 (-1.19%)
At close · Nov 17
View the 10-K filed Feb 26, 2026
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Customer concentration
— top 10 customers 24% of revenue
10 customers — 24% of revenue (the year ended December 31, 2025)
“Our ten largest customers accounted for 24% of revenues for the year ended December 31, 2025.”
Market Cap
$1.74B
Shares
152.54M
Volume · Nov 17
728.82K
Avg daily vol (3M)
2.65M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Faiz Mohammed | Interim Chief Financial Officer | Appointed | 2026-06-17 |
|
John E. Gallagher III
“Mr. Gallagher’s decision to resign was not the result of any disagreement with the Company, the Company’s management or any member of the Company’s Board of Directors, or on any matter relating to the Company’s operations, policies, practices, or financial reporting.”
|
Senior Vice President and Chief Financial Officer | Resigned | 2026-06-17 |
|
Cynthia Collins
“Ms. Collins advised the Company that her resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
Class II director | Resigned | 2026-03-31 |
| Jon Resnick | Class III member of the Board | Appointed | 2025-12-11 |
| Jon Resnick | Chief Executive Officer | Appointed | 2025-12-11 |
| Dr. Patrick F. Smith | President, Certara Drug Development Solutions | Resigned | 2025-03-05 |
| Dr. John V. W. Reynders | Class II director | Appointed | 2024-10-16 |
| John E. Gallagher III | Chief Financial Officer | Appointed | 2023-03-01 |
| Mason Slaine | member of the Board of Directors | Resigned | 2022-12-23 |
| David Spaight | Class I director with a term expiring at the Company's 2024 Annual Meeting of Shareholders | Appointed | 2022-12-08 |
| Ethan Waxman | member of the Board of Directors | Resigned | 2022-12-08 |
| Eric Liu | member of the Board of Directors | Resigned | 2022-12-08 |
| David Spaight | Board | Appointed | 2022-11-07 |
| Ethan Waxman | Board | Resigned | 2022-11-07 |
| Eric Liu | Board | Resigned | 2022-11-07 |
| Justin Edge | President of Regulatory and Access | Resigned | 2022-08-12 |
| Rosemary A. Crane | Class III director | Appointed | 2022-07-25 |
| Eran Broshy | Class III director | Appointed | 2022-07-13 |
Leadership
- Faiz Mohammed CFO
- John E. Gallagher III CFO
- Carol G. Gallagher Board Member
- David Spaight Board Member
- Dr. John V. W. Reynders Board Member
- Eran Broshy Board Member
- James E. Cashman III Board Member
- Jon Resnick Board Member
- Nancy Killefer Board Member
- Rosemary A. Crane Board Member
Key facts
CIK
1827090
CUSIP
15687V109
13F (30d)
260 filings
237 filers
Visit website
Investor relations